<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00107445</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02649</org_study_id>
    <secondary_id>UPCC-03804</secondary_id>
    <secondary_id>R21CA099346</secondary_id>
    <secondary_id>CDR0000419673</secondary_id>
    <nct_id>NCT00107445</nct_id>
  </id_info>
  <brief_title>EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer</brief_title>
  <official_title>Evaluation of Hypoxia by EF5 Binding in Gynecologic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well EF5 works in finding oxygen in tumor cells of&#xD;
      patients who are undergoing surgery or biopsy for cervical, endometrial, or ovarian&#xD;
      epithelial cancer. Diagnostic procedures using the drug EF5 to find oxygen in tumor cells may&#xD;
      help in planning cancer treatment&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Correlate the level of EF5 binding with pre-treatment hemoglobin level and tumor grade and&#xD;
      stage in patients undergoing surgery or biopsy for cervical, endometrial, or ovarian&#xD;
      epithelial cancer.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Correlate pre-treatment tumor hypoxia (as measured by EF5 binding) with time to&#xD;
      progression and time to recurrence in these patients.&#xD;
&#xD;
      II. Correlate EF5 binding with CD-31 expression (tumor vasculature), Ki-67 expression&#xD;
      (cellular proliferation), and erythropoietin signaling in these patients.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive EF5 IV over 1-2½ hours on day 1. Approximately 1-2 days later, patients&#xD;
      undergo tumor resection or biopsy. Patients' tumor tissue samples undergo&#xD;
      immunohistochemistry and flow cytometry to detect EF5 binding levels. Patients' blood is&#xD;
      drawn immediately before and 30-60 minutes and 1-2 days after receiving EF5 to measure&#xD;
      systemic EF5 binding levels.&#xD;
&#xD;
      Patients are followed at 30-45 days after administration of EF5 and then every 3-6 months&#xD;
      thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Level of EF5 binding</measure>
    <time_frame>Baseline</time_frame>
    <description>The relationship between the level of EF5 binding and hemoglobin will be summarized by Pearson's correlation coefficient.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoglobin level</measure>
    <time_frame>Baseline</time_frame>
    <description>The relationship between the level of EF5 binding and hemoglobin will be summarized by Pearson's correlation coefficient.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Analyzed using Kaplan-Meier procedures.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to recurrence</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Analyzed using Kaplan-Meier procedures.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <condition>Stage I Endometrial Carcinoma</condition>
  <condition>Stage I Ovarian Epithelial Cancer</condition>
  <condition>Stage IA Cervical Cancer</condition>
  <condition>Stage IB Cervical Cancer</condition>
  <condition>Stage II Endometrial Carcinoma</condition>
  <condition>Stage II Ovarian Epithelial Cancer</condition>
  <condition>Stage IIA Cervical Cancer</condition>
  <condition>Stage IIB Cervical Cancer</condition>
  <condition>Stage III Cervical Cancer</condition>
  <condition>Stage III Endometrial Carcinoma</condition>
  <condition>Stage III Ovarian Epithelial Cancer</condition>
  <condition>Stage IV Endometrial Carcinoma</condition>
  <condition>Stage IV Ovarian Epithelial Cancer</condition>
  <condition>Stage IVA Cervical Cancer</condition>
  <condition>Stage IVB Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (EF5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive EF5 IV over 1-2½ hours on day 1. Approximately 1-2 days later, patients undergo tumor resection or biopsy. Patients' tumor tissue samples undergo immunohistochemistry and flow cytometry to detect EF5 binding levels. Patients' blood is drawn immediately before and 30-60 minutes and 1-2 days after receiving EF5 to measure systemic EF5 binding levels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EF5</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (EF5)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed* diagnosis of 1 of the following:&#xD;
&#xD;
               -  Cervical cancer&#xD;
&#xD;
               -  Ovarian epithelial cancer&#xD;
&#xD;
               -  Endometrial cancer&#xD;
&#xD;
               -  Peritoneal cavity cancer&#xD;
&#xD;
          -  Requires surgery or biopsy for diagnosis or as standard initial treatment for the&#xD;
             tumor&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  WBC ≥ 2,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  No significant cardiac condition that would preclude study participation&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 1 month after study&#xD;
             participation&#xD;
&#xD;
          -  Weight ≤ 130 kg&#xD;
&#xD;
          -  No other significant medical condition that would preclude study participation&#xD;
&#xD;
          -  No scheduled chemotherapy for the tumor within the past 3 months&#xD;
&#xD;
          -  No scheduled radiotherapy to the tumor within the past 3 months&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina Chu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of The University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>April 5, 2005</study_first_submitted>
  <study_first_submitted_qc>April 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2005</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

